Your browser doesn't support javascript.
loading
Impact of Prior Use of Four Preventive Medications on Outcomes in Patients Hospitalized for Acute Coronary Syndrome--Results from CPACS-2 Study.
Li, Min; Huang, Yubei; Du, Xin; Li, Shenshen; Ji, Jiachao; Patel, Anushka; Gao, Runlin; Wu, Yangfeng.
Afiliação
  • Li M; Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China.
  • Huang Y; Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Du X; The George Institute for Global Health at Peking University Health Science Center, Beijing, China.
  • Li S; Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Ji J; The George Institute for Global Health at Peking University Health Science Center, Beijing, China.
  • Patel A; The George Institute for Global Health at Peking University Health Science Center, Beijing, China.
  • Gao R; The George Institute for Global Health, University of Sydney, Sydney, Australia.
  • Wu Y; The Department of Cardiology, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Bejing, China.
PLoS One ; 11(9): e0163068, 2016.
Article em En | MEDLINE | ID: mdl-27626640
ABSTRACT

BACKGROUND:

It is widely reported that long-term use of four preventive medications (antiplatelet agents, angiotensin converting enzyme inhibitor / angiotensin receptor blocker, statin and beta-blockers) reduce the risk of subsequent acute coronary syndromes (ACS). It is unclear whether these four medications benefit patients who develop ACS despite its use. METHODS AND

RESULTS:

Logistic regression and propensity-score was applied among 14790 ACS patients to assess the association between prior use of four preventive medications and in-hospital outcomes including severity of disease at presentation (type of ACS, systolic blood pressure <90 mmHg, and heart rate> = 100 beats/min), complicating arrhythmia and major adverse cardiovascular events (MACEs, including all deaths, non-fatal myocardial infarction or re-infarction, and non-fatal stroke). Prior use of each of the four medications was significantly associated with less severity of disease (ORs ranged from 0.40 to 0.82, all P<0.05), less arrhythmia (ORs ranged from 0.45 to 0.64, all P<0.05), and reduced risk of MACEs (ORs ranged from 0.59 to 0.73, all P<0.05) during hospitalization. Multiple variable-adjusted ORs of MACEs were 0.77, 0.67, 0.48 and 0.59 respectively in patients with 1, 2, 3 and 4 medications in comparison with patients with none, and other clinical outcomes showed the same trend (P for trend < 0.05).

CONCLUSIONS:

Among ACS patients in our study, those with prior use of four preventive medications presented with less disease severity, developed less arrhythmia and had a lower risk of in-hospital MACEs. The value of taking these medications may beyond just preventing occurrence of the disease.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores da Enzima Conversora de Angiotensina / Inibidores da Agregação Plaquetária / Antagonistas Adrenérgicos beta / Inibidores de Hidroximetilglutaril-CoA Redutases / Síndrome Coronariana Aguda Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores da Enzima Conversora de Angiotensina / Inibidores da Agregação Plaquetária / Antagonistas Adrenérgicos beta / Inibidores de Hidroximetilglutaril-CoA Redutases / Síndrome Coronariana Aguda Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article